Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of ...

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.

Gene sequencing technology company 10x Genomics (NASDAQ: TXG) hasn't been having it easy in the past few days on the stock ...

TXG BLFS NAGE AZTA ADPT MLAB Company Name 10x Genomics, Inc. BioLife Solutions, Inc. Niagen Bioscience, Inc. Azenta, Inc. Adaptive Biotechnologies Corporation Mesa Laboratories, Inc. Sector Health ...

10x Genomics TXG shares soared 8.2% in the last trading session to close at $16.99. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

10X GENOMICS ($TXG) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.36 per share, beating estimates of -$0.48 by $0.12 ...